Regulatory Requirements for Glove Integrity Testers and Analysis of 10 Common Audit Questions

Glove integrity test systems for isolators and RABS constitute core sterile barrier components within the manufacturing and quality control frameworks for sterile pharmaceuticals, biological preparations, vaccines and sterile testing laboratories. Minor damage or seal failure of gloves may trigger microbial ingress and cross-contamination, thereby undermining the sterility assurance level of products. For this reason, glove integrity testing has become a key verification item in GMP compliance management, routine quality control, NMPA unannounced inspections and overseas audits for pharmaceutical manufacturers. As dedicated testing equipment, glove integrity testers enable standardized, data-driven glove airtightness testing, helping enterprises align with industrial regulatory requirements and strengthen risk control systems for sterile production.

I. Basic Definition & Working Principle of Glove Integrity Testers

A glove integrity tester is specialized equipment designed for isolators and Restricted Access Barrier Systems (RABS) in pharmaceutical aseptic workshops and microbiology laboratories. It is primarily deployed to verify the airtightness and integrity of sterile operation gloves and sleeve assemblies, detecting microscopic cracks, pinholes, loose seals and other defects invisible to the naked eye.

The mainstream technology adopted is the pressure decay test principle. The system pressurizes, stabilizes pressure and depressurizes the sealed glove cavity, monitors pressure variation values, and judges whether leakage exists against pre-set compliant parameters. Two test modes are supported: in-situ online testing and offline standalone testing, covering full-cycle scenarios including incoming quality inspection of new gloves, batch testing of in-service gloves, re-inspection after equipment shutdown and restart, and annual validation. These devices are widely used in sterile preparations, biopharmaceuticals, medical devices and pharmaceutical quality control laboratories.

II. Applicable Regulatory Requirements & Industrial Standards for Glove Integrity Testing

Currently, no single dedicated standard exclusively governs glove integrity testing within domestic and international pharmaceutical industries. Relevant control requirements are dispersed across GMP specifications, pharmacopoeia guidelines, EU Annex 1 for sterile production and industrial technical guidance documents, which serve as universally accepted compliance references. Details are listed below:

1. Domestic Regulations & Standards

China NMPA GMP (Revised 2010) Appendix 1 explicitly stipulates that isolators and isolator sleeve/glove systems shall undergo routine monitoring and periodic leak testing to maintain stable and controllable sterile operating environments.

Guidelines for the Quality Management of Sterile Preparation Production further elaborates operational requirements, stating that isolator gloves shall generally undergo integrity testing before and after each production batch. Additional test frequencies may be implemented for continuous production based on risk assessment.

General Chapter 9206 of the Chinese Pharmacopoeia specifies integrity validation requirements for isolators used in sterility testing. It clarifies that glove systems, as core isolator components, shall be included in overall validation and routine monitoring. Meanwhile, industrial standard YY/T 0567.6—2022 defines detailed procedures for qualification, monitoring and revalidation of isolator glove systems.

2. International Regulations & Industrial Guidelines

EU GMP Annex 1 (2022 Revision) establishes clear specifications for glove testing of sterile barrier systems. Enterprises are required to conduct risk assessments under their Contamination Control Strategy (CCS) and perform periodic glove integrity testing via validated methods. Test results shall be incorporated into batch production records and environmental monitoring data for retention.

US FDA 21 CFR Part 11 applies to manufacturers conducting export business and subject to overseas GMP audits. It mandates full integrity and traceability of electronic test data and operation audit trails to guarantee authentic, auditable records.

In addition, ISO 14644-7 (Cleanrooms and associated controlled environments – Separative devices) and PDA Technical Report No.34 provide industrial references for test method selection, risk assessment and equipment validation.

III. High-Frequency Inspection Questions from Pharmaceutical Regulatory Audits & Compliance Interpretations

Summarized from recent NMPA unannounced inspections, provincial drug authority audits and overseas GMP audits, these 10 frequently raised inquiries, supported by current regulations and common industrial practices, serve as benchmarks for quality, validation and engineering personnel in pharmaceutical companies.

1. Q1: How to define routine test frequency for sterile gloves; is pre-batch and post-batch testing mandatory?

   In line with domestic sterile preparation guidelines and EU GMP Annex 1, the widely accepted compliant practice requires integrity testing for isolator/RABS gloves prior to and upon completion of each production batch. For multi-shift continuous, non-stop production, enterprises may formulate intermittent sampling and daily verification protocols supported by risk assessment. Re-leak testing is recommended after equipment shutdown, prolonged idle storage and re-commissioning; gloves can only be deployed upon passing the test.

2. Q2: Are uniform defect aperture criteria (e.g., 100 μm, 200 μm) mandatory for glove leak testing?

   No unified mandatory aperture threshold is specified in prevailing domestic and international regulations, pharmacopoeia and industrial standards. Aperture values serve as common industry references. Enterprises shall determine appropriate test sensitivity and acceptance criteria based on product sterility risks, glove materials and production conditions through risk assessment. Corresponding test methods must undergo method validation to ensure effective detection of micro-leakages posing risks to sterility.

3. Q3: Do glove integrity testers require periodic calibration and routine metrology management?

   Pressure and vacuum sensing core components of glove integrity testers are susceptible to accuracy drift. Classified as critical pharmaceutical metrology equipment, they require regular calibration. Common industrial practice includes interim checks on a short-term basis and full annual calibration performed by qualified third-party institutions. Calibration certificates and deviation evaluation records shall be retained to ensure consistent test accuracy.

4. Q4: What constitutes the standard closed-loop response workflow when glove leak testing fails?

   A compliant closed-loop management process for failed test results includes multiple steps: immediately halt production at the corresponding workstation and lock equipment access; identify root causes to distinguish glove body damage, joint seal failure or equipment parameter abnormality; replace with qualified gloves and conduct re-testing; carry out risk review and deviation assessment for batches manufactured between the last passing test and the failed test; fully archive failure records, corrective actions, re-test data and deviation reports to form a complete control loop.

5. Q5: Must glove test data comply with 21 CFR Part 11 data integrity requirements?

   For enterprises engaged in export business, subject to FDA/EU audits or manufacturing sterile products for overseas markets, glove testing generates critical sterile quality control data that generally needs to satisfy 21 CFR Part 11 requirements. Equipment shall support hierarchical access management, comprehensive audit trails, electronic signatures and raw data archiving, capturing operator identity, test timestamp, parameter settings, test curves and pass/fail judgements to mitigate compliance risks such as manual tampering, missing data and manual entry. Domestic-only manufacturers may adopt relevant functions selectively based on audit needs and internal quality systems.

6. Q6: Are both online and offline test modes acceptable for compliance? Can the two modes be used interchangeably?

   Both in-situ online testing and offline standalone testing are recognized compliant approaches applicable to different scenarios. Online testing is deployed for routine batch monitoring under actual operating conditions; offline testing is adopted for incoming inspection of new gloves, re-testing of damaged gloves and annual comprehensive validation. Enterprises shall formalize fixed test modes according to production scenarios. If alternating the two modes, rationality must be demonstrated via risk assessment and method validation, with clear specifications documented in SOPs to stabilize the testing framework.

7. Q7: Is 100% individual integrity testing required for newly purchased sterile gloves?

   Microscopic defects invisible to visual inspection may arise during the production, warehousing and transportation of sterile gloves, creating latent sterility risks. The mainstream compliant practice requires full individual leak testing for newly received and newly installed sterile gloves before acceptance and installation. A glove inventory log shall be established to trace the full lifecycle including incoming inspection, deployment and scrappage.

8. Q8: Is a complete IQ/OQ/PQ equipment validation package mandatory for glove integrity testers?

   As critical quality control equipment for sterile production, glove integrity testers generally require full validation packages. Installation Qualification (IQ) verifies compliance of installation environment and hardware configuration; Operational Qualification (OQ) confirms stable performance of equipment parameters, test functions, alarm systems and data traceability; Performance Qualification (PQ) validates long-term precision and reliability under simulated production conditions. Complete validation documentation serves as core supporting material for regulatory inspections.

9. Q9: How to guarantee traceable accountability of test data for multi-station, multi-shift operations?

   Multi-workstation operations often lead to data confusion and unclear accountability. Enterprises can optimize control via hierarchical access control, binding operator accounts and associating workstation information. Intelligent equipment equipped with RFID recognition enables automatic one-to-one correlation between operators, test stations, glove serial numbers and test data, strengthening traceability to meet audit requirements.

10. Q10: What retention periods apply to glove testing-related records?

    In accordance with pharmaceutical archive management and GMP requirements, raw test data, reports, equipment calibration records, deviation handling documents and validation files for glove integrity testing shall normally be retained for no less than 5 years. Test records associated with marketed medicinal products may be retained longer based on product shelf life and traceability obligations. Electronic records shall be backed up periodically to ensure long-term retrievability.

IV. Summary on Industry Compliance Development

With continuous refinement of domestic and international sterile production regulations and rising standards for regulatory inspections, glove integrity testing has evolved from a routine equipment operation into an essential component of the Contamination Control Strategy. Beyond equipment testing precision, standardized test workflows, robust data traceability systems and closed-loop risk response mechanisms have become primary focus areas during NMPA unannounced inspections and overseas audits.

Pharmaceutical manufacturers may optimize internal SOP systems based on applicable regulations and production conditions, deploy compliant, intelligent glove integrity testing equipment, and standardize full workflows covering daily testing, equipment validation and record retention. This supports enterprises in mitigating risks related to sterile production and aligns with the evolving compliance landscape of the industry.